Immunome Inc.

NASDAQ: IMNM · Real-Time Price · USD
10.26
0.32 (3.22%)
At close: Aug 15, 2025, 3:46 PM

Immunome Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
12.59M 10.94M 9.04M 10.13M 10.78M 12.68M 14.02M 10.19M 6.63M 2.36M n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
2.61M 2.56M 2.1M 1.76M 1.36M 843K 728K 731K 679K 643K 631K 489K 661K 715K 755K 637K 351K 176K
Gross Profit
12.59M 10.94M 9.04M 10.13M 10.62M 12.36M 13.55M 9.46M 5.95M 1.72M -631K -489K -661K -715K -755K -637K -351K -176K
Operating Income
-224.61M -218.14M -305.8M -317.48M -271.59M -237.36M -109.53M -22.66M -26.57M -29.72M -36.9M -36.96M -36.15M -32.96M -25.2M -21.43M -16.53M -13.5M
Interest Income
12.22M 13.03M 12.84M 12.13M 9M 5.33M 2.72M 706K 419K 205K 5K 4K 3K 1K n/a n/a n/a 5K
Pretax Income
-212.39M -205.11M -292.96M -305.35M -262.59M -232.03M -106.81M -21.96M -26.15M -29.51M -36.9M -36.96M -36.15M -32.47M -24.71M -20.93M -21.59M -19.06M
Net Income
-212.39M -205.11M -292.96M -305.35M -262.59M -232.03M -106.61M -22.38M -26.56M -29.93M -37.51M -36.96M -36.15M -32.47M -24.71M -20.93M -21.59M -19.06M
Selling & General & Admin
40.7M 37.64M 32.95M 30.55M 25.4M 22.74M 19.66M 15.15M 14.09M 12.97M 13.63M 13.55M 13.45M 12.75M 11.09M 9.87M 7.84M 6.15M
Research & Development
162.41M 151.04M 129.54M 91.29M 57.91M 34.55M 23.09M 17.7M 19.11M 19.11M 23.27M 23.41M 22.69M 20.21M 14.11M 11.56M 8.69M 7.35M
Other Expenses
34.08M 40.39M 152.34M 205.77M 198.9M 192.59M 80.64M -166K n/a n/a n/a -3K 3K 503K 503K 506K 500K n/a
Operating Expenses
237.19M 229.07M 314.84M 327.61M 282.21M 249.88M 123.38M 32.69M 33.19M 32.08M 36.9M 36.96M 36.15M 32.96M 25.2M 21.43M 16.53M 13.5M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a 4K 4K 4K 4K 5K 8K 9K 10K 16K 23K 22K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
237.19M 229.07M 314.84M 327.61M 282.38M 250.04M 123.55M 32.86M 33.19M 32.08M 36.9M 36.96M 36.15M 32.96M 25.2M 21.43M 16.53M 13.5M
Income Tax Expense
n/a n/a n/a n/a n/a 34.91K -166.09K 451.92K 450.92K 414K 614K 2K 12K 15K 16K 10K 11K 10K
Shares Outstanding (Basic)
87.01M 79.41M 62.7M 60.21M 59.94M 10.31M 21.95M 12.2M 12.2M 12.18M 12.13M 12.13M 12.06M 12.12M 11.93M 11.88M 11.39M 10.64M
Shares Outstanding (Diluted)
87.01M 79.41M 62.7M 60.21M 59.94M 10.31M 21.95M 12.2M 12.2M 12.18M 12.13M 12.13M 12.13M 12.12M 11.93M 11.93M 11.46M 10.64M
EPS (Basic)
-3.08 -3.18 -15.22 -18.16 -17.74 -17.6 -5.37 -1.84 -2.18 -2.46 -3.09 -3.06 -3.01 -2.73 -2.14 -1.88 -2.06 -1.89
EPS (Diluted)
-3.08 -3.18 -15.22 -18.16 -17.74 -17.6 -5.37 -1.84 -2.18 -2.46 -3.09 -3.06 -3.01 -2.73 -2.14 -1.88 -2.06 -1.89
EBITDA
-187.92M -175.18M -151.35M -109.94M -71.17M -43.76M -28M -21.93M -25.88M -29.07M -36.27M -36.47M -35.49M -32.25M -24.45M -20.53M -21.28M -18.27M
EBIT
-190.53M -177.75M -153.46M -111.71M -72.53M -44.6M -28.73M -22.66M -26.57M -29.72M -36.9M -36.96M -36.15M -32.96M -25.21M -21.42M -22.07M -19.04M
Depreciation & Amortization
2.61M 2.56M 2.1M 1.76M 1.36M 843K 728K 731K 679K 643K 631K 489K 661K 715K 755K 893K 784K 768K